SpringWorks Therapeutics SWTX
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
SpringWorks Therapeutics (SWTX) Core Market Data and Business Metrics
Latest Closing Price
$46.52Price-Earnings Ratio
-13.37Total Outstanding Shares
74.94 Million SharesDividend
No dividendSIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQHeadquarters
100 Washington Boulevard, Stamford, CT, 06902
Historical Stock Splits
If you bought 5 shares of SWTX before March 17, 2011, you'd have 1 share today.
| Execution Date | Split Amount |
|---|---|
| March 17, 2011 | 1-for-5 (Reverse Split) |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 2,421,562 Shares | 3.11 | 3/14/2025 | 7,528,338 Shares |
| 2,963,173 Shares | 2.4 | 2/28/2025 | 7,108,935 Shares |
| 4,232,157 Shares | 2.15 | 2/14/2025 | 9,106,626 Shares |
| 1,251,602 Shares | 11.51 | 1/31/2025 | 14,403,281 Shares |
| 2,252,830 Shares | 6.06 | 1/15/2025 | 13,660,654 Shares |
| 1,005,666 Shares | 12.2 | 12/31/2024 | 12,268,610 Shares |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow, Continuing | $-106.29 Million |
| Net Cash Flow From Financing Activities, Continuing | $4.76 Million |
| Net Cash Flow From Investing Activities, Continuing | $64.55 Million |
| Net Cash Flow From Financing Activities | $4.76 Million |
| Net Cash Flow From Operating Activities, Continuing | $-175.60 Million |
| Net Cash Flow From Operating Activities | $-175.60 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Diluted Average Shares | $74.13 Million |
| Income/Loss From Equity Method Investments | $-6 Million |
| Research and Development | $200.52 Million |
| Net Income/Loss | $-258.13 Million |
| Income/Loss From Continuing Operations After Tax | $-258.13 Million |
| Net Income/Loss Attributable To Parent | $-258.13 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $-259.02 Million |
| Comprehensive Income/Loss | $-259.02 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss Attributable To Parent | $-887,000 |
| Other Comprehensive Income/Loss | $-259.02 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Cash | $461.90 Million |
| Other Current Liabilities | $56.53 Million |
| Fixed Assets | $19.68 Million |
| Inventory | $10.21 Million |
| Noncurrent Liabilities | $6.18 Million |
| Noncurrent Assets | $206.81 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||